dexcom deliv strong first quarter come
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data jun
rate updat jun
currenc amount express
valuat growth profit
methodolog valu compani
despit well-establish track record introduc
precis sensor use continu glucos monitor
firm main focu enhanc accuraci cgm
perform may enough fend competit
strength technolog captur impress
slice cgm market howev contend sever
factor histor hinder abil expand cgm
market view bigger opportun moreov
tougher competit abbott could hurt
use larg center among type diabet
penetr estim around partli
relat greater need patient pool versu type
keep closer tab blood glucos read similarli payer
reluct expand reimburs beyond type
popul meant face uphil battl
expand type market
abbott introduc meaning innov
realm think could sway patient away
abbott freestyl libr flash significantli user-friendli
requir pain finger stick calibr devic
aggress price expect product make substanti
inroad type popul new insulin
pump autom much insulin deliveri come
integr cgm new competit featur could
outweigh improv accuraci stick-fre featur sensor life
recent approv next-gen product
factor work favor first
precis cgm remain materi better competit
firm establish medicar
reimburs cgm basi accuraci
enjoy head start angl though abbott recent
secur medicar reimburs new cgm final
dexcom allianc tandem verili googl
healthcar incub provid opportun firm
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
design commerci continu glucos monitor cgm
system diabet cgm system serv altern tradit
glucomet process compani sell three differ piec
equip sensor transmitt receiv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
dexcom deliv strong first quarter
come rais fair valu estim may
dexcom first-quart result exceed expect
weve moder rais fair valu estim
adjust reflect robust demand new monitor
set full commerci launch june weve
incorpor optimist estim thank new
featur includ factori calibr new
insert system pediatr indic abbott
freestyl libr flash offer compel price point
stand-alone cgm guardian connect offer
exclus access sugar predict power think
well-known accuraci user-friendli aspect
keep well posit compet nonetheless
yet give moat firm remain
year away meaning profit
influx competit innov cgm market
although manag rais outlook revenu
million think new rang rather conserv
easili exceed launch
strong anticip despit earlier-than-expect
approv next-gen product ad littl first-
quarter revenu growth fuel primarili
product mind weve increas estim
sensor growth partial off-set free upgrad
transmitt put project
full-year revenu million somewhat beyond
million high point manag outlook
continu expect turn corner
profit firm make progress scale
meantim much innov diabet
devic market well keep eye connect
integr dexcom insulet omnipod
tandem slim pump collabor get closer
hybrid closed-loop system similar medtron
could give anoth foothold competit
share
adjust
valuat growth profit may
moder boost fair valu estim
earlier-than-expect approv robust
respons full commerci launch set begin june
yet reach profit firm continu invest
build manufactur footprint sale
infrastructur scale develop next five year
expect post meaning profit
overal forecast revenu compound-annual-growth-rate
roughli half histor norm reflect
competit abbott thu far
diversifi rival plagu delay approv
manufactur constraint issu behind
firm recent approv medtron
minim abbott freestyl libr devic
lower price point think take
grant user perhap first time
sever compel altern choos
larger revenu base
expect reach gross margin
oper margin expect
launch two gener no-calibr
devic creat verili furthermor
facil launch arizona weigh oper
near term expect support recent
medicar approv remov key barrier kept
older patient away
consid relianc singl product
current inabl earn profit tougher competit
abbott give high
uncertainti rate base case estim larg
depend abil expand within type
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bear-cas scenario abbott chip away
domin market posit faster expect
anticip abbott first mover advantag type
space hurt launch
target user desir integr cgm nearli
closed-loop insulin pump combin scenario
model revenu compound annual growth rate
next year bear-cas fair valu estim
point think dug moat
similar firm earli stage fast growth
sub-scal oper yet reach profit
expect turn corner cross
black could easili delay thank
moat diagnost stem either switch cost
cost structur yet creat competit
advantag either area sever reason first
switch cost second diagnost dexcom
face difficulti link diagnost healthcar
outcom closer linkag outcom stronger
manufactur negoti payer
recogn made progress front
recent therapeut indic mean patient
make treatment decis base read without
confirm blood glucos level tradit meter
howev simpli go far enough opinion
key rival offer competit cgm
integr insulin pumpth actual therapeut
deviceand instruct pump much
insulin releas remain far closer
therapi happen cgm enabl
therapi
diabet market unit state patient
popul transit tradit blood glucos meter
cgm devic abbott late approv
no-calibr product creat sell-off stock
expect news flow could continu hit dexcom
bullish scenario assum intern creat
headwind continu stymi abbott
initi fail gain substanti foothold
space leav opportun solidifi
posit newer product like devic verili
product expand market opportun factori
calibr attract user previous entic
cgm devic given dynam forecast
type diabet patient type popul
transit devic fast rate furthermor dexcom
begin valid type non-intens
market particularli
newer verily-partn
product allow compani appeal
rapidli grow type market scenario project
revenu compound annual growth rate
next year bull-cas fair valu estim per
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
freestyl libr flash offer similar
featur includ factori calibr fda
approv dose decis howev libr flash
price significantli lower expect
especi sensor
automat shut day wear
third also face disadvantag type market
mani cgm user also use insulin
pump allianc product
integr tandem anima pump
offer pump hold estim
share insulin pump market tandem
anima hold less addit johnson
 johnson recent announc would discontinu
manufactur anima product encourag
patient transit integr
pump cgm system
final think meaning hybrid closed-loop
innov attract competit pump
user well convert type pump
multipl daili inject anticip
patient opt medtron guardian cgm
integr pump instead keep two
separ devic monitor pump
final suspect manag made deliber
decis focu gain market share expens
profit weve seen sort competit
price strategi usual employ smaller
competitor seek enter market
well-establish competitor alreadi domin
competit price aid new entrant carv slice
market situat face
claim alreadi hold lion share cgm
market addit dexcom
wide
acknowledg technolog leader even
competitor accur sensor
consist roll improv cgm technolog
sixth-gener product
technolog innov associ market share
leadership usual characterist moati firm
wield price power case weve seen littl
evid translat technolog
superior long-term price power exampl
dexcom sensor last seven day price
per day asp manag alreadi
indic would hold steadi asp
sensor even though new product last day
could potenti lower revenu
higher-margin consum depend mani
current patient use sensor indic
think face neg moat trend
first long-held ambit penetr sizabl
segment type market need multipl daili
insulin inject could benefit cgm use thu far
payer gener reluct establish
reimburs among group patient
kept limit smaller type market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
next-gen continu glucos monitor
offer greater accuraci longer sensor life
ojohnson johnson decis exit pump
busi direct anima user medtron
omedicar decis reimburs
favor develop privat payer
often use medicar
benchmark
ountil privat payer decid expand
reimburs includ type diabet dexcom
larg limit type market
must face behemoth
owhil littl detail initi
verili think great potenti appli tech
expertis data analyt data-intens health
manag diabet partnership could put
step ahead competitor
omor attract price abbott
could substanti cut adopt rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
cash flow posit four consecut
year yet post year posit earn
revenu grown quickli research develop
expens sell gener administr cost
grown significantli well sometim outpac
revenu growth financi fund
oper loss addit capit rais
year convert debt took
substanti debt rel histor level
issu million convert senior note
matur intent financ
signific expans particularli buildout
compani manufactur facil arizona note
initi convers rate share common stock
per princip amount note equat
per share common stock signific
premium current price
consid relianc singl product
current inabl earn profit tougher competit
abbott give high
uncertainti rate dexcom greatest materi risk
better-than-expect adopt competit product
opinion alreadi expect strong adopt
abbott freestyl libr flash
guardian cgm market recept exce
optimist expect would bear brunt
addit pure play cgm opportun
financi well-being sole base growth one
type product unlik main competitor wide
diversifi progress abbott might make
expand reimburs could also hurt
share longer term doubt
whether technolog leadership enough
allow commerci success continu believ
type type intens diabet continu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
seek product improv well-b make
solid underli demand howev think may
cede market share abbott
product improv accuraci offer addit featur
asid competit risk
also face gener medic devic risk
includ run afoul fda potenti product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
gregg serv ceo eventu step
serv execut chairman role
maintain today former kevin sayer becam ceo
interest gregg sayer previous
serv role minim diabet manag system
acquir billion
believ experi may give manag team
addit insight diabet market
think manag long-term focu innov
sound like reach
creat strateg partnership busi
alphabet life scienc divis verili priorit
watch applaud manag invest creat
digit ecosystem around cgm data particularli
cgm info fed io android devic manag
diabet extrem data intens well suit
app would equip patient act cgm
read time manner
littl critic firm capit alloc
perspect remain earli stage
commerci high growth technolog
adopt manag continu invest next
improv strateg
allianc time posit
face decis alloc excess cash
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
dexcom deliv strong first quarter
come rais fair valu estim may
dexcom first-quart result exceed expect
weve moder rais fair valu estim
adjust reflect robust demand new monitor
set full commerci launch june weve
incorpor optimist estim thank new
featur includ factori calibr new
insert system pediatr indic abbott
freestyl libr flash offer compel price point
stand-alone cgm guardian connect offer
exclus access sugar predict power think
well-known accuraci user-friendli aspect
keep well posit compet nonetheless
yet give moat firm remain
year away meaning profit
influx competit innov cgm market
although manag rais outlook revenu
million think new rang rather conserv
easili exceed launch
strong anticip despit earlier-than-expect
approv next-gen product ad littl first-
quarter revenu growth fuel primarili
product mind weve increas estim
sensor growth partial off-set free upgrad
transmitt put project
full-year revenu million somewhat beyond
million high point manag outlook
continu expect turn corner
profit firm make progress scale
meantim much innov diabet
devic market well keep eye connect
integr dexcom insulet omnipod
tandem slim pump collabor get closer
hybrid closed-loop system similar medtron
could give anoth foothold competit
initi dexcom moat neg moat
despit well-establish track record
introduc precis sensor use
continu glucos monitor firm main focu
enhanc accuraci cgm perform may
enough fend competit tougher competit
enter pictur think must contend
per share think share fulli valu
point think dug moat
suffer low switch cost
diagnost also face difficulti link
diagnost healthcar outcom closer linkag
outcom stronger manufactur negoti
payer recogn made
progress front recent therapeut indic
may enough sway payer away
compel featur competit product
similar firm earli stage fast growth
sub-scal oper yet reach profit
expect turn corner cross
black could easili delay thank
abbott introduc meaning
innov realm think could siphon patient
away abbott freestyl libr flash
significantli user-friendli requir pain
finger stick calibr devic aggress
price expect product make substanti inroad
type popul new insulin
pump autom much insulin deliveri come
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
integr cgm new competit
featur could outweigh improv accuraci sensor
life anticip next-gen product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
